Compare Crispr Therapeutics AG (CRSP) vs F5 Inc (FFIV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs F5 Inc — how do they compare? Crispr Therapeutics AG trades at $53.51 (market cap $4.88B), while F5 Inc trades at $480.89 (market cap $26.14B). The key difference: F5 Inc is far larger — about 5.4× Crispr Therapeutics AG's market cap, and F5 Inc is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and F5 Inc for 38 Days on average.
| CRSP | FFIV | |
|---|---|---|
Market Cap | $4.88B | $26.14B |
Volume | 2,861,747 | 503,146 |
Sector | Health | Technology |
52-Week High | $74.92 | $469.79 |
52-Week Low | $44.34 | $223.99 |
Typical Hold Time | 77 Days | 38 Days |
Enterprise Value | $3.30B | $24.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.41, up 2.02% with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with -$581.60M net income in 2025 and revenue volatility, though analyst consensus remains bullish with a $67.83 price target. Key catalysts include upcoming clinical data presentations for autoimmune disease therapies and CASGEVY commercialization progress.
The stock presents high-risk, high-reward potential with strong Wall Street support (57.9% buy ratings) but faces significant execution risks. Near-term performance hinges on clinical trial outcomes and revenue generation from approved therapies, while persistent cash burn and competitive pressures remain key concerns for investors.
F5 (FFIV) trades at $479.83, up 2.82% today and near its 52-week high, reflecting strong momentum. The stock shows bullish technical signals with recent earnings beats and robust revenue growth, reaching $3.09 billion in 2025. Positive sentiment is driven by leadership in AI security and strategic partnerships, though valuation multiples like a P/E of 36.78 suggest premium pricing. Cash flow remains healthy with $268 million net inflow in 2025, supporting operational strength.
Outlook is cautiously optimistic with growth in AI and security markets offering upside, but risks include high valuation and competitive pressures. Analysts are mixed with a $416.60 consensus target below current price, indicating potential overvaluation. Investors should weigh solid fundamentals against elevated multiples for balanced risk-reward.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About F5 Inc
F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.
Read more on FFIV →
